Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPD | P32754 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365929 | 0.82 | PDE5A (0.53) | PDE9APDE1APDE1BPDE1CHPGD | |
| SCHEMBL6367469 | 0.80 | PDE9A (0.52) | DPYDMPOPDE9APDE1APDE1B | |
| SCHEMBL6366619 | 0.79 | DPYD (0.46) | DPYDMPOPDE9APDE1APDE1B | |
| SCHEMBL6366302 | 0.78 | PDE1A (0.41) | PDE9APDE1APDE1BPDE1CPNP | |
| SCHEMBL6371780 | 0.76 | PLA2G2A (0.43) | ALDH1A1HPGDKMT2A | |
| SCHEMBL6368262 | 0.75 | CXCR2 (0.38) | PDE9APDE1APDE1BPDE1CPARP14 | |
| SCHEMBL6371852 | 0.74 | PDE2A (0.39) | ALPL | |
| SCHEMBL3492585 | 0.72 | PDE1A (0.56) | PDE9APDE1APDE1BPDE1CNPSR1 | |
| SCHEMBL6366909 | 0.72 | HSP90AA1 (0.43) | ALPLPDE9AALDH1A1HPGDIGF1R | |
| SCHEMBL6367286 | 0.71 | LMNA (0.40) | PARP14HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | DPYD 1935/4885MPO 2156/4885ALPL 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.